Head, Oncology Clinical Development - ADCs
Leads the end-to-end clinical development of an antibody-drug conjugate (ADC) oncology asset across multiple tumor types, from first-in-human through registrational trials and launch readiness. Responsible for shaping clinical strategy, overseeing global trials, engaging with regulatory authorities, and leading cross-functional teams in a matrixed environment. Involves governance leadership, scientific advisory boards, and integration of innovative approaches such as AI/ML and real-world evidence to accelerate development.